Michael Lowley
Atlanta, GANPI 1063894418
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 128 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 17 manufacturers reported payments, led by Supernus Pharmaceuticals, Inc. at 36.0% of the total. 2025 is the largest year on record at $844, more than ten times the $44 reported in 2019.
Across 128 payments — averaging $21.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Supernus Pharmaceuticals, Inc.$970
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$331
- Corium, LLC$238
- Alkermes, Inc.$181
- Teva Pharmaceuticals USA, Inc.$162
- Johnson & Johnson$135
- plus $680 from 11 others
What the payments were for
- Food & beverage$2,698100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.